Dextropropoxyphene ban in India: Is there a case for reconsideration?
- PMID: 24554903
- PMCID: PMC3917176
- DOI: 10.4103/0976-500X.124406
Dextropropoxyphene ban in India: Is there a case for reconsideration?
Conflict of interest statement
Comment on
- J Pharmacol Pharmacother. 5(1):1.
Similar articles
-
India urged to reverse dextropropoxyphene ban.Lancet Oncol. 2013 Aug;14(9):e344. doi: 10.1016/s1470-2045(13)70331-0. Lancet Oncol. 2013. PMID: 24058965 No abstract available.
-
Is tapentadol a potential Trojan horse in the postdextropropoxyphene era in India?Indian J Pharmacol. 2018 Jan-Feb;50(1):44-46. doi: 10.4103/ijp.IJP_21_17. Indian J Pharmacol. 2018. PMID: 29861527 Free PMC article.
-
Sex selection in India: Why a ban is not justified.Dev World Bioeth. 2020 Sep;20(3):150-156. doi: 10.1111/dewb.12250. Epub 2019 Oct 23. Dev World Bioeth. 2020. PMID: 31642181
-
Dextropropoxyphene overdose. Epidemiology, clinical presentation and management.Med Toxicol Adverse Drug Exp. 1987 Nov-Dec;2(6):430-44. doi: 10.1007/BF03259877. Med Toxicol Adverse Drug Exp. 1987. PMID: 3323775 Review.
-
Dextropropoxyphene: safety and efficacy in older patients.Drugs Aging. 2005;22(5):419-32. doi: 10.2165/00002512-200522050-00006. Drugs Aging. 2005. PMID: 15903354 Review.
Cited by
-
Importance of pesticides for lethal poisoning in India during 1999 to 2018: a systematic review.BMC Public Health. 2021 Jul 22;21(1):1441. doi: 10.1186/s12889-021-11156-2. BMC Public Health. 2021. PMID: 34294076 Free PMC article.
-
Ban on Dextropropoxyphene is Unjustifiable.Indian J Palliat Care. 2015 Jan-Apr;21(1):3-7. doi: 10.4103/0973-1075.150148. Indian J Palliat Care. 2015. PMID: 25709176 Free PMC article. No abstract available.
References
-
- New Delhi: Government of India; 2013. The Gazette of India No 252. Ministry of Health And Family Welfare (Department of Health and Family Welfare)
-
- Medicines and Healthcare products Regulatory Agency. Withdrawal of co-proxamol products and interim updated prescribing information 2005 Contract No.: CEM/CMO/2005/2. [Accessed on 2013 Dec 22]. Available at http://www.mhra.gov.uk/home/groups/pl-a/documents/websiteresources/con01... .
-
- London: EMEA European Medicines Agency; 2009. EMEA European Medicines Agency. European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines.
-
- USFDA. Guidance for Industry – E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 2005. 2010 - PubMed
-
- Simkin S, Hawton K, Sutton L, Gunnell D, Bennewith O, Kapur N. Co-proxamol and suicide: Preventing the continuing toll of overdose deaths. QJM. 2005;98:159–70. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources